Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193462 | 0.96 | SERPINE1 (0.53) | CA2CA1NR1I2ITGB1ITGA4 | |
| SCHEMBL3204698 | 0.93 | NR1I2 (0.53) | CA2CA1NR1I2MEN1ALDH1A1 | |
| SCHEMBL3185435 | 0.90 | SERPINE1 (0.52) | CA2CA1NR1I2ITGB1ITGA4 | |
| SCHEMBL4764668 | 0.82 | CA1 (0.49) | CA2CA1ITGB1ITGA4MEN1 | |
| SCHEMBL3194968 | 0.81 | NTSR1 (0.60) | NR1I2SERPINE1NTSR1MMP9 | |
| SCHEMBL3193084 | 0.79 | NTSR1 (0.59) | NR1I2ALDH1A1SERPINE1NTSR1 | |
| SCHEMBL3328211 | 0.79 | NTSR1 (0.59) | NR1I2ALDH1A1SERPINE1NTSR1 | |
| SCHEMBL3198713 | 0.78 | SERPINE1 (0.52) | NR1I2MEN1KMT2APPARGSERPINE1 | |
| SCHEMBL3195444 | 0.77 | NR1I2 (0.63) | CA2CA1NR1I2MEN1ALDH1A1 | |
| SCHEMBL5418798 | 0.77 | SERPINE1 (0.56) | NR1I2MEN1KMT2APPARGSERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137363-A1 | Substituted Indoles And Methods Of Their Use | WYETH LLC (US) | 2010-06-03 | — | — | US | claimed |
| US-7683091-B2 | Substituted indoles and methods of their use | WYETH (US) | 2010-03-23 | — | — | US | claimed |
| US-20070043101-A1 | Substituted indoles and methods of their use | WYETH (US) | 2007-02-22 | — | — | US | claimed |
| US-20100137363-A1 | Substituted Indoles And Methods Of Their Use | WYETH LLC (US) | 2010-06-03 | — | — | US | disclosed |
| US-7683091-B2 | Substituted indoles and methods of their use | WYETH (US) | 2010-03-23 | — | — | US | disclosed |
| EP-1919866-A2 | SUBSTITUTED INDOLES AND USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20070043101-A1 | Substituted indoles and methods of their use | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007022321-A2 | SUBSTITUTED INDOLES AND USE THEREOF | WYETH (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043101-A1 | Substituted indoles and methods of their use | INMT, AANAT, IDO2 | CA2 2597/4885CA1 861/4885NR1I2 2818/4885 |
| US-20100137363-A1 | Substituted Indoles And Methods Of Their Use | INMT, AANAT, IDO2 | CA2 2597/4885CA1 861/4885NR1I2 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.